Video

Dr. Petrylak Explains Prostate Cancer Clinical Trial Difficulties

Author(s):

Daniel P. Petrylak, MD

In Partnership With:

Daniel P. Petrylak, MD, from Columbia University Medical Center Explains the Difficulties Facing During Prostate Cancer Clinical Trials

Daniel P. Petrylak, MD, Professor of Medicine, Program Director of the Genitourinary Oncology Section in the Division of Hematology/Oncology and Co-Leader, Prostate Cancer in the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center Explains the Difficulties Facing During Prostate Cancer Clinical Trials

Related Videos
Fred Saad, CQ, MD, FRCS, FCAHS
Eric Kumar Singhi, MD
Seth Wander, MD, PhD
Lillian L. Siu, MD, FRCPC
Marc Machaalani, MD
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD
Related Content
Bertram Yuh, MD, MISM, MSHCPM
September 30th 2024

Prostate Cancer Awareness Efforts Target Patient Education, Treatment Access, and Survivorship Care

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Casper H.J. van Eijck, MD, PhD
September 19th 2024

Rintatolimod Plus Durvalumab Shows Early Disease Control in Late-Stage Pancreatic Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Silke Gillessen, MD, of Università della Svizzera italiana
September 14th 2024

Addition of Radium-223 to Enzalutamide Significantly Improves rPFS and OS in mCRPC

The OncFive: Top Oncology Articles for the Week of 9/1
September 7th 2024

The OncFive: Top Oncology Articles for the Week of 9/1